According to new findings published in Science Translational Medicine, Cleveland Clinic researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer.

The team, led by Nima Sharifi, M.D., of Cleveland Clinic's Lerner Research Institute, demonstrated that inhibiting the protein H6PD led to significantly reduced tumour sizes and improved survival among mouse models with drug-resistant prostate cancer.

The H6PD levels also were elevated in biopsied patient tumours, suggesting the protein might be targeted in patients for treatment.

"New treatment approaches for drug-resistant prostate cancer are desperately needed," said Dr Sharifi, director of Cleveland Clinic's Genitourinary Malignancies Research Center. "These findings suggest an entirely new strategy for the treatment of men with this aggressive form of prostate cancer."

Enzalutamide, a current standard-of-care hormone therapy for metastatic prostate cancer, works by blocking androgen receptors, which are proteins that help drive cancer cells. While initially effective, most patients eventually develop resistance to the treatment.

This resistance occurs when androgen receptors are blocked and cancer cells adapt to get their "fuel" from a similar receptor, called the glucocorticoid receptor.
These glucocorticoid receptors bind to and interact with the stress hormone cortisol.

In an earlier study published in eLife, Dr Sharifi and his team linked enzalutamide resistance to increased tumour cortisol levels. They found that tumours typically express a protein called 11β-HSD2, which inactivates cortisol.

However, when this protein expression is inhibited in some tumours, cortisol and the glucocorticoid receptor are stimulated and become available for use by cancer cells.

"Taken together, our study findings suggest that pharmacologically inhibiting the H6PD protein can reverse drug resistance in prostate cancer cells," said Dr Sharifi. "By blocking this protein, we can prevent cancer cells from utilising their backup fuel supply - cortisol and its receptor.

When we block this pathway, tumours begin to become responsive to standard treatments again."

In this new study, the researchers demonstrated that, in addition to decreased expression of 11β-HSD2, resistant tumours also have increased H6PD levels.
"With lower levels of 11β-HSD2, which normally functions to cut off the fuel supply to drug-resistant cancer cells, the cells are free to continue to grow and spread unchecked," said Dr Sharifi.

"By inhibiting the H6PD protein, however, we were able to reinstate anti-cortisol effects. This finding is key to better understanding how disruptions in cortisol metabolism contribute to cancer cells' growth and spread."

Dr Sharifi's clinical collaborator Eric Klein, M.D., chair of Cleveland Clinic's Urology & Kidney Institute and a co-author on the study, said, "We found elevated levels of H6PD in both animal models and patient tissues, particularly after treating tumours with enzalutamide.

These findings hold promise for novel precision medicine approaches in the management of men with aggressive prostate cancer."

The researchers targeted H6PD with rucaparib, a drug already approved by the U.S. Food and Drug Administration. Dr Sharifi collaborated with scientists from Cleveland Clinic's Center for Therapeutics Discovery to identify what parts of rucaparib are chemically necessary to inhibit the protein.

Researchers administered enzalutamide to mouse models of aggressive prostate cancer that expressed H6PD and those where the protein was blocked with rucaparib. The models where H6PD was blocked had significantly smaller tumours and longer progression-free survival following enzalutamide treatment.

Source: Cleveland Clinic